Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05089643

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Metastatic Triple-Negative Breast Cancer Clinical Trial

Official title:
Anrotinib in Combination With Capecitabine in the Single-arm, Open Phase II Treatment of Relapsed or Metastatic Triple-negative Breast Cancer Clinical Research

Clinical Trial Summary

The hypothesis of this study is to discover if the capecitabine plus Anlotinib can shrink or slow the growth of pretreated advanced TNBC. It is a single-arm phase II clinical study of capecitabine combined with antinib in the treatment of recurrent or metastatic triple-negative breast cancer

Clinical Trial Description

It is a single-arm phase II clinical study of capecitabine combined with antinib in the treatment of recurrent or metastatic triple-negative breast cancer. The hypothesis of this study is to discover if the capecitabine plus Anlotinib can shrink or slow the growth of pretreated advanced TNBC. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05089643
Study type Interventional
Source Chinese Academy of Medical Sciences
Contact Peng Yuan, doctor
Phone 18612621749
Email sunlight_1985@163.com
Status Recruiting
Phase Phase 2
Start date April 11, 2019
Completion date December 31, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04986852 - Olinvacimab With Pembrolizumab in Patients With mTNBC Phase 2
Recruiting NCT05831553 - TIP in Patients Affected by Metastatic TNBC
Recruiting NCT05570253 - A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer Phase 2
Active, not recruiting NCT04454437 - Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments Phase 2
Recruiting NCT05101096 - Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05227664 - A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer Phase 2
Suspended NCT04250818 - Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile
Completed NCT03004183 - SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC Phase 2
Recruiting NCT06027268 - Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer Phase 2
Not yet recruiting NCT05746728 - Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer Phase 1/Phase 2